Jump to content

FDA approves lung cancer drug Alimta


Recommended Posts

FDA approves lung cancer drug Alimta

WASHINGTON (AP) — The Food and Drug Administration approved a cancer drug made by pharmaceutical giant Eli Lilly and Co. to treat advanced non-small cell lung cancer in patients who have undergone chemotherapy.

According to the American Cancer Society, non-small cell lung cancer is the leading cause of cancer-related deaths in the nation. By the time most patients arrive for treatment, the cancer is widespread.

The drug, Alimta, in clinical trials was found to shrink tumors as effectively as another cancer drug, Taxotere. But Alimta did so with fewer troubling side effects, including hair loss, depressed blood count and hospitalizations for subsequent infection.

The treatment, 500 mg every 21 days, costs patients $3,900 per month, according to the company.

"There's no question, the survival was comparable to the survival with the best drugs we have," said Dr. Paul Bunn, director of the University of Colorado Cancer Center and principal investigator for several of the drug's clinical trials. "As a doctor, this drug is as good as anything else we have. It does benefit patients."

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.